UMIN-CTR Clinical Trial

Unique ID issued by UMIN UMIN000038131
Receipt number R000043449
Scientific Title Evaluation of SpaceOAR System when used to Create Space Between the Rectum and Prostate in Adult Men Undergoing First Time LDR Brachytherapy Monotherapy for Treatment of Localized Prostate Cancer
Date of disclosure of the study information 2019/10/18
Last modified on 2021/09/30 13:06:47

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information

Public title

Evaluation of SpaceOAR System when used to Create Space Between the Rectum and Prostate in Adult Men Undergoing First Time LDR Brachytherapy Monotherapy for Treatment of Localized Prostate Cancer

Acronym

SpaceOAR system PMS

Scientific Title

Evaluation of SpaceOAR System when used to Create Space Between the Rectum and Prostate in Adult Men Undergoing First Time LDR Brachytherapy Monotherapy for Treatment of Localized Prostate Cancer

Scientific Title:Acronym

SpaceOAR system PMS

Region

Japan


Condition

Condition

Prostate cancer

Classification by specialty

Urology Radiology

Classification by malignancy

Malignancy

Genomic information

NO


Objectives

Narrative objectives1

To obtain post market patient information of the SpaceOAR System injected between the rectum and prostate in adult men undergoing first time LDR brachytherapy (LDR-BT) monotherapy for treatment of localized prostate cancer.

Basic objectives2

Safety,Efficacy

Basic objectives -Others


Trial characteristics_1


Trial characteristics_2


Developmental phase

Phase IV


Assessment

Primary outcomes

- Mean mid gland (axial) perirectal space following SpaceOAR hydrogel implantation (mm).
- Change in prostate dimensions before and after SpaceOAR placement.

Key secondary outcomes

- Percent of patients meeting the rectum radiation dose constraints
- Change in dosimetry data from Pre-placement to Day 1 and Day 30; including, radiation doses delivered to the prostate, rectum and urethra
- Percent of patients who experience a SpaceOAR procedural adverse event
- Percent and grade of patients experiencing rectal and urinary toxicity assessed via CTCAE v.4.0. Acute (implant to 3 months) and late (3 to 15 months) toxicity will be evaluated
- All adverse events, device malfunctions and all serious adverse events


Base

Study type

Interventional


Study design

Basic design

Single arm

Randomization

Non-randomized

Randomization unit


Blinding

Open -no one is blinded

Control

Uncontrolled

Stratification


Dynamic allocation


Institution consideration


Blocking


Concealment



Intervention

No. of arms

1

Purpose of intervention

Treatment

Type of intervention

Device,equipment

Interventions/Control_1

SpaceOAR system

Interventions/Control_2


Interventions/Control_3


Interventions/Control_4


Interventions/Control_5


Interventions/Control_6


Interventions/Control_7


Interventions/Control_8


Interventions/Control_9


Interventions/Control_10



Eligibility

Age-lower limit


Not applicable

Age-upper limit


Not applicable

Gender

Male

Key inclusion criteria

Men undergoing LDR Brachytherapy monotherapy for localized Prostate Cancer in accordance with the IFU and Appropriate Use Document.

Key exclusion criteria

NA

Target sample size

46


Research contact person

Name of lead principal investigator

1st name Kazuo
Middle name
Last name Kawahara

Organization

Boston Scientific Japan K.K.

Division name

Clinical Sciences

Zip code

164-0001

Address

4-10-2 Nakano, Nakano-ku, Tokyo, Japan

TEL

03-6853-7500

Email

kazuo.kawahara@bsci.com


Public contact

Name of contact person

1st name Ayako
Middle name
Last name Oda

Organization

Boston Scientific Japan K.K.

Division name

Clinical Sciences

Zip code

164-0001

Address

4-10-2 Nakano, Nakano-ku, Tokyo, Japan

TEL

03-6853-7500

Homepage URL


Email

Ayako.Oda@bsci.com


Sponsor or person

Institute

Boston Scientific Japan K.K.

Institute

Department

Personal name



Funding Source

Organization

Boston Scientific Japan K.K.

Organization

Division

Category of Funding Organization

Profit organization

Nationality of Funding Organization



Other related organizations

Co-sponsor


Name of secondary funder(s)



IRB Contact (For public release)

Organization

Not applicable

Address

Not applicable

Tel

Not applicable

Email

Not applicable


Secondary IDs

Secondary IDs

NO

Study ID_1


Org. issuing International ID_1


Study ID_2


Org. issuing International ID_2


IND to MHLW



Institutions

Institutions



Other administrative information

Date of disclosure of the study information

2019 Year 10 Month 18 Day


Related information

URL releasing protocol


Publication of results

Unpublished


Result

URL related to results and publications


Number of participants that the trial has enrolled

55

Results


Results date posted


Results Delayed


Results Delay Reason


Date of the first journal publication of results


Baseline Characteristics


Participant flow


Adverse events


Outcome measures


Plan to share IPD


IPD sharing Plan description



Progress

Recruitment status

Completed

Date of protocol fixation

2018 Year 05 Month 18 Day

Date of IRB

2018 Year 05 Month 18 Day

Anticipated trial start date

2018 Year 11 Month 08 Day

Last follow-up date

2021 Year 01 Month 25 Day

Date of closure to data entry


Date trial data considered complete


Date analysis concluded



Other

Other related information



Management information

Registered date

2019 Year 09 Month 27 Day

Last modified on

2021 Year 09 Month 30 Day



Link to view the page

Value
https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000043449


Research Plan
Registered date File name

Research case data specifications
Registered date File name

Research case data
Registered date File name